Deficiency in the production of antibodies to lipids correlates with increased lipid metabolism in severe COVID-19 patients
Copyright © 2023 Piédrola, Martínez, Gradillas, Villaseñor, Alonso-Herranz, Sánchez-Vera, Escudero, Martín-Antoniano, Varona, Ruiz, Castellano, Muñoz and Sádaba..
Background: Antibodies to lipids are part of the first line of defense against microorganisms and regulate the pro/anti-inflammatory balance. Viruses modulate cellular lipid metabolism to enhance their replication, and some of these metabolites are proinflammatory. We hypothesized that antibodies to lipids would play a main role of in the defense against SARS-CoV-2 and thus, they would also avoid the hyperinflammation, a main problem in severe condition patients.
Methods: Serum samples from COVID-19 patients with mild and severe course, and control group were included. IgG and IgM to different glycerophospholipids and sphingolipids were analyzed using a high-sensitive ELISA developed in our laboratory. A lipidomic approach for studying lipid metabolism was performed using ultra-high performance liquid chromatography coupled to electrospray ionization and quadrupole time-of-flight mass spectrometry (UHPLC-ESI-QTOF-MS).
Results: Mild and severe COVID-19 patients had higher levels of IgM to glycerophosphocholines than control group. Mild COVID-19 patients showed higher levels of IgM to glycerophosphoinositol, glycerophosphoserine and sulfatides than control group and mild cases. 82.5% of mild COVID-19 patients showed IgM to glycerophosphoinositol or glycerophosphocholines plus sulfatides or glycerophosphoserines. Only 35% of severe cases and 27.5% of control group were positive for IgM to these lipids. Lipidomic analysis identify a total of 196 lipids, including 172 glycerophospholipids and 24 sphingomyelins. Increased levels of lipid subclasses belonging to lysoglycerophospholipids, ether and/or vinyl-ether-linked glycerophospholipids, and sphingomyelins were observed in severe COVID-19 patients, when compared with those of mild cases and control group.
Conclusion: Antibodies to lipids are essential for defense against SARS-CoV-2. Patients with low levels of anti-lipid antibodies have an elevated inflammatory response mediated by lysoglycerophospholipids. These findings provide novel prognostic biomarkers and therapeutic targets.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 14(2023) vom: 30., Seite 1188786 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Piédrola, Ignacio [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.07.2023 Date Revised 18.07.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2023.1188786 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359277071 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359277071 | ||
| 003 | DE-627 | ||
| 005 | 20231226210620.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2023.1188786 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359277071 | ||
| 035 | |a (NLM)37426663 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Piédrola, Ignacio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Deficiency in the production of antibodies to lipids correlates with increased lipid metabolism in severe COVID-19 patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.07.2023 | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Piédrola, Martínez, Gradillas, Villaseñor, Alonso-Herranz, Sánchez-Vera, Escudero, Martín-Antoniano, Varona, Ruiz, Castellano, Muñoz and Sádaba. | ||
| 520 | |a Background: Antibodies to lipids are part of the first line of defense against microorganisms and regulate the pro/anti-inflammatory balance. Viruses modulate cellular lipid metabolism to enhance their replication, and some of these metabolites are proinflammatory. We hypothesized that antibodies to lipids would play a main role of in the defense against SARS-CoV-2 and thus, they would also avoid the hyperinflammation, a main problem in severe condition patients | ||
| 520 | |a Methods: Serum samples from COVID-19 patients with mild and severe course, and control group were included. IgG and IgM to different glycerophospholipids and sphingolipids were analyzed using a high-sensitive ELISA developed in our laboratory. A lipidomic approach for studying lipid metabolism was performed using ultra-high performance liquid chromatography coupled to electrospray ionization and quadrupole time-of-flight mass spectrometry (UHPLC-ESI-QTOF-MS) | ||
| 520 | |a Results: Mild and severe COVID-19 patients had higher levels of IgM to glycerophosphocholines than control group. Mild COVID-19 patients showed higher levels of IgM to glycerophosphoinositol, glycerophosphoserine and sulfatides than control group and mild cases. 82.5% of mild COVID-19 patients showed IgM to glycerophosphoinositol or glycerophosphocholines plus sulfatides or glycerophosphoserines. Only 35% of severe cases and 27.5% of control group were positive for IgM to these lipids. Lipidomic analysis identify a total of 196 lipids, including 172 glycerophospholipids and 24 sphingomyelins. Increased levels of lipid subclasses belonging to lysoglycerophospholipids, ether and/or vinyl-ether-linked glycerophospholipids, and sphingomyelins were observed in severe COVID-19 patients, when compared with those of mild cases and control group | ||
| 520 | |a Conclusion: Antibodies to lipids are essential for defense against SARS-CoV-2. Patients with low levels of anti-lipid antibodies have an elevated inflammatory response mediated by lysoglycerophospholipids. These findings provide novel prognostic biomarkers and therapeutic targets | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a lysophosphatidylethanolamine | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a IgM | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a lipidomic | |
| 650 | 4 | |a lysophosphatidylcholine | |
| 650 | 4 | |a natural antibodies | |
| 650 | 4 | |a phosphatidylinositol | |
| 650 | 7 | |a glycerylphosphoinositol |2 NLM | |
| 650 | 7 | |a 16824-65-0 |2 NLM | |
| 650 | 7 | |a Sphingomyelins |2 NLM | |
| 650 | 7 | |a Sulfoglycosphingolipids |2 NLM | |
| 650 | 7 | |a Glycerophospholipids |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 700 | 1 | |a Martínez, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Gradillas, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Villaseñor, Alma |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso-Herranz, Vanesa |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Vera, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Escudero, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Antoniano, Isabel A |e verfasserin |4 aut | |
| 700 | 1 | |a Varona, Jose Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Castellano, Jose María |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, Úrsula |e verfasserin |4 aut | |
| 700 | 1 | |a Sádaba, María C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 14(2023) vom: 30., Seite 1188786 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g day:30 |g pages:1188786 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2023.1188786 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |b 30 |h 1188786 | ||